Literature DB >> 11546768

26 S proteasome-mediated degradation of topoisomerase II cleavable complexes.

Y Mao1, S D Desai, C Y Ting, J Hwang, L F Liu.   

Abstract

DNA topoisomerase II (TOP2) cleavable complexes represent an unusual type of DNA damage characterized by reversible TOP2-DNA cross-links and DNA double strand breaks. Many antitumor drugs and physiological stresses are known to induce TOP2 cleavable complexes leading to apoptotic cell death and genomic instability. However, the molecular mechanism(s) for repair of TOP2 cleavable complexes remains unclear. In the current studies, we show that TOP2 cleavable complexes induced by the prototypic TOP2 poison VM-26 are proteolytically degraded by the ubiquitin/26 S proteasome pathway. Surprisingly the TOP2beta isozyme is preferentially degraded over TOP2alpha isozyme. In addition, transcription inhibitors such as 5,6-dichlorobenzimidazole riboside and camptothecin can substantially block VM-26-induced TOP2beta degradation. These results are consistent with a model in which the repair of TOP2beta cleavable complexes may involve transcription-dependent proteolysis of TOP2beta to reveal the protein-concealed double strand breaks.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11546768     DOI: 10.1074/jbc.M104009200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

1.  The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.

Authors:  Hai Xiao; Yong Mao; Shyamal D Desai; Nai Zhou; Chun-Yuan Ting; Jaulang Hwang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

2.  Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta.

Authors:  Yi Lisa Lyu; James C Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-28       Impact factor: 11.205

Review 3.  Application of DNA microarrays in pharmacogenomics and toxicogenomics.

Authors:  Khew-Voon Chin; A N Tony Kong
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

4.  Concentration-response studies of the chromosome-damaging effects of topoisomerase II inhibitors determined in vitro using human TK6 cells.

Authors:  P Gollapudi; V S Bhat; D A Eastmond
Journal:  Mutat Res       Date:  2019-05-15       Impact factor: 2.433

Review 5.  DNA-protein crosslinks from environmental exposure: Mechanisms of formation and repair.

Authors:  Yusuke Kojima; Yuichi J Machida
Journal:  Environ Mol Mutagen       Date:  2020-07-09       Impact factor: 3.216

6.  Tyrosine 656 in topoisomerase IIβ is important for the catalytic activity of the enzyme: Identification based on artifactual +80-Da modification at this site.

Authors:  Adrian G Grozav; Belinda B Willard; Toshiyuki Kozuki; Kenichi Chikamori; Marius A Micluta; Andrei-Jose Petrescu; Michael Kinter; Ram Ganapathi; Mahrukh K Ganapathi
Journal:  Proteomics       Date:  2011-01-31       Impact factor: 3.984

Review 7.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

8.  The ubiquitin-conjugating enzyme E2-EPF is overexpressed in primary breast cancer and modulates sensitivity to topoisomerase II inhibition.

Authors:  Donato Tedesco; Jianhuan Zhang; Lan Trinh; Guita Lalehzadeh; Rene Meisner; Ken D Yamaguchi; Daniel L Ruderman; Harald Dinter; Deborah A Zajchowski
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

9.  Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.

Authors:  Anna M Azarova; Yi Lisa Lyu; Chao-Po Lin; Yuan-Chin Tsai; Johnson Yiu-Nam Lau; James C Wang; Leroy F Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-19       Impact factor: 11.205

10.  Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.

Authors:  Shyamal D Desai; Hui Zhang; Alexandra Rodriguez-Bauman; Jin-Ming Yang; Xiaohua Wu; Murugesan K Gounder; Eric H Rubin; Leroy F Liu
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.